High grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris N, et al. IARC Publications Website – WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues [Internet]. WHO/IARC Classif. Tumours, 4th Ed. Vol. 2. 2012. p. 202–208.
   Google Scholar
• Friedberg JW. Double-hit diffuse large B-cell lymphoma. J Clin Oncol. 2012;30(28):3439–3443.
   PubMed Web of Science ®Google Scholar
• Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson cancer center clinical experience. Br J Haematol. 2014;166(6):891–901.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Mato AR, Gerson JN, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol. 2017;35(20):2260–2267.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Mei M, Low L, et al. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol. 2017;35(1):24–31.
   PubMed Web of Science ®Google Scholar
• Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–2361.
   PubMed Web of Science ®Google Scholar
• Dunleavy K. Double-hit lymphomas: current paradigms and novel treatment approaches. Hematology Am Soc Hematol Educ Program. 2014;2014(1):107–112.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. How I treat double-hit lymphoma. Blood. 2017;130(5):590–596.
   PubMed Web of Science ®Google Scholar
• Hilton LK, Tang J, Ben-Neriah S, et al. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood. 2019;134(18):1528–1532.
   PubMed Web of Science ®Google Scholar
• Collinge B, Ben-Neriah S, Chong L, et al. The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood. 2021;137(16):2196–2208.
   PubMed Web of Science ®Google Scholar
• Medane S, Pastoret C, Moignet Autrel A, et al. Mutational analysis using NGS shows frequent targetable mutations in double-hit and triple-hit high grade B-cell lymphoma (HGBL) and detects TNFAIP3 mutations in transformed cases. EHA. 2018;:3252.
   Google Scholar
• Zech L, Haglund U, Nilsson K, et al. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer. 1976;17(1):47–56.
   PubMed Web of Science ®Google Scholar
• Bloomfield CD, Levine EG, Peterson BA, et al. Nonrandom chromosome abnormalities in lymphoma. Cancer Res. 1983;43(6):2975–2984.
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Johansson B, Åkerman M, et al. Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas. Eur J Haematol. 1999;62(3):184–190.
   PubMed Web of Science ®Google Scholar
• Juneja S, Matthews J, Lukeis R, et al. Prognostic value of cytogenetic abnormalities in previously untreated patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1997;25(5-6):493–501.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Bens S, Advani R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg lymphoma biomarker consortium. J Clin Oncol. 2019;37(35):3359–3368.
   PubMed Web of Science ®Google Scholar
• Chong LC, Ben-Neriah S, Slack GW, et al. High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. Blood Adv. 2018;2(20):2755–2765.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298–303.
   PubMed Web of Science ®Google Scholar
• Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012;109(10):3879–3884.
   PubMed Web of Science ®Google Scholar
• Schuetz JM, Johnson NA, Morin RD, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia. 2012;26(6):1383–1390.
   PubMed Web of Science ®Google Scholar
• Pillonel V, Juskevicius D, Ng CKY, et al. High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations. Leukemia. 2018;32(11):2412–2426.
   PubMed Web of Science ®Google Scholar
• Correia C, Schneider PA, Dai H, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 2015;125(4):658–667.
   PubMed Web of Science ®Google Scholar
• Albert T, Urlbauer B, Kohlhuber F, et al. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in burkitt’s lymphoma cell lines. Oncogene. 1994;9(3):759–763.
   PubMed Web of Science ®Google Scholar
• Kabrani E, Chu VT, Tasouri E, et al. Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells. Blood. 2018;132(25):2670–2683.
   PubMed Web of Science ®Google Scholar
• Trinh DL, Scott DW, Morin RD, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121(18):3666–3674.
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181–185.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433–1442.
   PubMed Web of Science ®Google Scholar
• Huang YH, Cai K, Xu PP, et al. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct Target Ther. 2021;6.
   Web of Science ®Google Scholar
• Akl H, Monaco G, Decrock E, et al. Abstract B42: the regulation of the ER-mitochondria-Ca2+ cross-talk by bcl-2 and Bcl-XL: a new scenario for the development of selective tools in oncology? 2013;:B42–B42.
   Google Scholar
• Deng X, Gao F, Flagg T, et al. Bcl2's flexible loop domain regulates p53 binding and survival. Mol Cell Biol. 2006;26(12):4421–4434.
   PubMed Web of Science ®Google Scholar
• Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature. 1994;369(6478):321–323.
   PubMed Web of Science ®Google Scholar